Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| MCRA | INDUSTRY |
Not provided
Not provided
Not provided
Prospective, Single Center, Open Label Clinical Study. The purpose of the study is to collect safety data associated with the use of the OsteoProbe System. Study Duration is expected to take approximately 3 months from first subject enrolled to the last follow-up visit.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OsteoProbe System | Device | The OsteoProbe® System ("OsteoProbe") is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation. |
| Measure | Description | Time Frame |
|---|---|---|
| The Number of Participants With Reported Device Related Serious Adverse Events. | The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol. | Procedure |
| The Number of Participants With Reported Device Related Serious Adverse Events. | The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System. | 1-day follow up visit |
| The Number of Participants With Reported Device Related Serious Adverse Events. | The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System. | 7-day follow up visit |
| The Number of Participants With Reported Device Related Serious Adverse Events. | The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol. | 30-day follow up visit |
| Measure | Description | Time Frame |
|---|---|---|
| NRS Pain Scores | The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Active skin infection at the procedure site as identified during a SOC physical examination.
Subject-reported or known systemic infection;
Subject-reported or known allergy to local anesthetic;
Subject-reported or known allergy to stainless steel or nickel materials;
Subject-reported or known current use of systemic antibiotics, or topical antibiotics administered to the procedure site;
Subject-reported or known history of needle phobia;
Significant soft tissue at the procedure site which would preclude use of the OsteoProbe in the judgement of the Investigator;
Known instance of hardware in the tibia that is intended to be measured based on radiographic imaging;
Known instance of a previous or current fracture in the tibia that is intended to be measured based on radiographic imaging;
Are known to be actively participating or known to have participated in another clinical investigation for which they received an investigational product (including but not limited to a drug or vaccine) within the last 90 days, or reports that they intend to participate in another clinical investigation during the course of the study;
Are known to be currently abusing drugs or alcohol or have a known history of the same within the last 12 months;
Have any known or subject reported mental or psychological disorders that, in the judgement of the Investigator, would impair their ability to accurately complete the NRS Pain Score surveys;
Are currently a prisoner;
Have a condition which, in the judgement of the Investigator, would preclude adequate evaluation of the device's safety and performance. Conditions include but are not limited to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Meridian Clinical Research, LLC. | Omaha | Nebraska | 68134 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | OsteoProbe System | OsteoProbe System: The OsteoProbe® System ("OsteoProbe") is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | OsteoProbe System | OsteoProbe System: The OsteoProbe® System ("OsteoProbe") is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Number of Participants With Reported Device Related Serious Adverse Events. | The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol. | Posted | Count of Participants | Participants | Procedure |
|
|
30 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | OsteoProbe System | OsteoProbe System: The OsteoProbe® System ("OsteoProbe") is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Joint Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Nicole Harris | MCRA, LLC | 202-552-5800 | 5823 | nharris@mcra.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 21, 2020 | Feb 26, 2021 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Post-procedure, 1-day, 7-day and 30-day follow up visits |
| BMSi Scores | BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality. | Procedure |
| Number of Participants With Adverse Events | The number of participants who experienced an adverse event. | Procedure through day 30 |
| Number of Participants With Device-related Adverse Events | The number of participants who experienced an device-related adverse event. | Procedure through day 30 |
| Number of Participants With Serious Adverse Events | The number of participants who experienced a Serious adverse event. | Procedure through day 30 |
| Unanticipated Adverse Device Effects (UADE) | The number of participants who experienced a Unanticipated adverse device effects. | Procedure through day 30 |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Participants |
|
|
| Primary | The Number of Participants With Reported Device Related Serious Adverse Events. | The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System. | Posted | Count of Participants | Participants | 1-day follow up visit |
|
|
|
| Primary | The Number of Participants With Reported Device Related Serious Adverse Events. | The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System. | Posted | Count of Participants | Participants | 7-day follow up visit |
|
|
|
| Primary | The Number of Participants With Reported Device Related Serious Adverse Events. | The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol. | Posted | Count of Participants | Participants | 30-day follow up visit |
|
|
|
| Secondary | NRS Pain Scores | The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure). | Posted | Mean | Standard Deviation | score on a scale | Post-procedure, 1-day, 7-day and 30-day follow up visits |
|
|
|
| Secondary | BMSi Scores | BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality. | Posted | Mean | Standard Deviation | score | Procedure |
|
|
|
| Secondary | Number of Participants With Adverse Events | The number of participants who experienced an adverse event. | Posted | Count of Participants | Participants | Procedure through day 30 |
|
|
|
| Secondary | Number of Participants With Device-related Adverse Events | The number of participants who experienced an device-related adverse event. | Posted | Count of Participants | Participants | Procedure through day 30 |
|
|
|
| Secondary | Number of Participants With Serious Adverse Events | The number of participants who experienced a Serious adverse event. | Posted | Count of Participants | Participants | Procedure through day 30 |
|
|
|
| Secondary | Unanticipated Adverse Device Effects (UADE) | The number of participants who experienced a Unanticipated adverse device effects. | Posted | Count of Participants | Participants | Procedure through day 30 |
|
|
|
| 0 |
| 40 |
| 0 |
| 40 |
| 1 |
| 40 |
Not provided
Not provided